Liquidia Corp Ordinary Shares LQDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $27.99
- Day Range
- $26.31–29.18
- 52-Week Range
- $21.35–93.61
- Bid/Ask
- $28.57 / $28.60
- Shares Outstanding
- 89.51M
- Market Cap
- $2.56B
- Volume/Avg
- 8M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 19.89
- Price/Sales
- 5.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 216
- Website
- https://www.liquidia.com
Valuation
|
Metric
|
LQDA
|
|---|---|
Price/Earnings (Normalized) | 19.89 |
Price/Book Value | 12.78 |
Price/Sales | 5.83 |
Price/Cash Flow | 12.86 |
Price/Earnings
LQDA
Financial Strength
|
Metric
|
LQDA
|
|---|---|
Quick Ratio | 2.07 |
Current Ratio | 2.31 |
Interest Coverage | 6.33 |
Quick Ratio
LQDA
Profitability
|
Metric
|
LQDA
|
|---|---|
Return on Assets (Normalized) | 46.51% |
Return on Equity (Normalized) | 215.22% |
Return on Invested Capital (Normalized) | 67.02% |
Return on Assets
LQDA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|Ps<#Dtl | LOCK|<zbM | $67B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|BDCb$SPf | LOCK|^%WQ | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|#!WwQC& | LOCK|%V | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|RC?SfK@k | LOCK|yMW | $29B | |||
| Viatris Inc
VTRS
| LOCK|yyDjCm | LOCK|>p | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|CB | LOCK|QH | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|$vFt>DK | LOCK|?< | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|@>!sWhD | LOCK|wl | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|K^>kXk | LOCK|Ft%dJ | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|J^fd$&w | LOCK|Lx | $2B |
United States